Inscriere cercetatori

Site nou !

Daca nu va puteti recupera parola (sau aveti alte probleme), scrieti-ne la pagina de contact. Situl vechi se gaseste la adresa old.ad-astra.ro

LIPOSOMAL NANODELIVERY SYSTEM FOR PROTEASOME INHIBITOR ANTICANCER DRUG BORTEZOMIB

Butu, A; Rodino, S; Golea, D; Butu, M; Negoescu, C; Dinu–Pirvu, C.E. BUTNARIU, M. Liposomal nanodelivery system for proteasome inhibitor anticancer drug bortezomib. Farmacia, (eISSN: 2065–0019. Volume: 63, Issue: 2, Pages: 224–229, Accession Number: WOS: 000353526900011, ISSN: 0014–8237, Published: MAR–APR 2015), IF(2014): 1.005.

Hide ResearcherID and ORCID

Author ResearcherID ORCID Number
BUTNARIU, Monica http://orcid.org/0000-0002-2032-5000
BUTU, Alina http://orcid.org/0000-0001-8171-4352
Dinu-Pirvu, Cristina-Elena http://orcid.org/0000-0003-1704-7887

FARMACIA, ISSN: 0014-8237, eISSN: 2065-0019, Volume: 63, Issue: 2, Pages: 224-229, Published: MAR-APR 2015

Abstract: Bortezomib is the first therapeutic agent designed to inhibit mainly the activity of the 26S proteasome. It is used for the treatment of multiple myeloma. The objective of this study was to develop and optimize liposomal formulation of bortezomib in order to improve the encapsulation efficiency. For evaluating the encapsulation efficiency it was investigated the effect of two parameters: the drug/lipid molar ratio and the pH of the medium. The liposomal formulation of bortezomib was obtained by mixing a solution of bortezomib with SUV liposomes (small unilamellar vesicle). A transmembrane pH gradient was obtained by creating a difference of pH between internal medium of the liposomes and the external medium in which the liposomes were suspended. When preparing the liposomes by using a pH gradient it was obtained an encapsulation efficiency of 48 % for the molar ratio bortezomib:lipid 1:5.
SOC STINTE FARMACEUTICE ROMANIA, BUCURESTI, STR TRAIAN VUIA 6, SECT 1, BUCURESTI, 020956, ROMANIA
Research Areas: Pharmacology & Pharmacy

Web of Science Categories: Pharmacology & Pharmacy

Document Type: Article, Accession Number: WOS:000353526900011